THE USE OF THE AGENT FOR INDUCING IMMUNITY TO SARS-COV-2
The disclosed invention relates to safe and efficacious methods of extending postvaccinal immunity against severe acute respiratory syndrome virus SARS-CoV-2 and revaccinating a population against diseases caused by SARS-CoV-2. The disclosed methods include administration of an agent to a person or population. The agent may include a first component comprising an expression vector based on a genome of recombinant strain of (i) human adenovirus serotype 26 with the E1 and E3 sites deleted from the genome and the site ORF6-Ad26 substituted for ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, or (ii) a simian adenovirus serotype 25 with the E1 and E3 sites deleted from the genome with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The first component of the agent is combined or replaced with a second component in the form of an expression vector based on a genome of recombinant strain of human adenovirus serotype 5 with the E1 and E3 sites deleted from the genome with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In addition to the above, the method may include administering an agent as disclosed herein, wherein the first component or the second component has the form of an expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 27. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-27, Last update posted on www.tib.eu: 2024-01-03, Last updated: 2024-01-12 |
|---|
| Patentnummer: |
EP4295153 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018910866 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018910866 | ||
| 003 | DE-627 | ||
| 005 | 20240112063403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240105s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018910866 | ||
| 035 | |a (EPA)EP4295153 | ||
| 035 | |a (EPA)81845625 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZUBKOVA OLGA VADIMOVNA |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a THE USE OF THE AGENT FOR INDUCING IMMUNITY TO SARS-COV-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-27, Last update posted on www.tib.eu: 2024-01-03, Last updated: 2024-01-12 | ||
| 520 | |a The disclosed invention relates to safe and efficacious methods of extending postvaccinal immunity against severe acute respiratory syndrome virus SARS-CoV-2 and revaccinating a population against diseases caused by SARS-CoV-2. The disclosed methods include administration of an agent to a person or population. The agent may include a first component comprising an expression vector based on a genome of recombinant strain of (i) human adenovirus serotype 26 with the E1 and E3 sites deleted from the genome and the site ORF6-Ad26 substituted for ORF6-Ad5 with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, or (ii) a simian adenovirus serotype 25 with the E1 and E3 sites deleted from the genome with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The first component of the agent is combined or replaced with a second component in the form of an expression vector based on a genome of recombinant strain of human adenovirus serotype 5 with the E1 and E3 sites deleted from the genome with an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In addition to the above, the method may include administering an agent as disclosed herein, wherein the first component or the second component has the form of an expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a A61B: Diagnosis; surgery; identification (analysing biological material g01n, e.g. g01n0033480000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a med | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a OZHAROVSKAIA TATIANA ANDREEVNA |4 aut | |
| 700 | 0 | |a DOLZHIKOVA INNA VADIMOVNA |4 aut | |
| 700 | 0 | |a POPOVA OLGA |4 aut | |
| 700 | 0 | |a SHCHEBLIAKOV DMITRII VIKTOROVICH |4 aut | |
| 700 | 0 | |a GROUSOVA DARIA MIKHAILOVNA |4 aut | |
| 700 | 0 | |a DZHARULLAEVA ALINA SHAHMIROVNA |4 aut | |
| 700 | 0 | |a TUKHVATULIN AMIR ILDAROVICH |4 aut | |
| 700 | 0 | |a TUKHVATULINA NATALIA MIKHAILOVNA |4 aut | |
| 700 | 0 | |a SHCHERBININ DMITRII NIKOLAEVICH |4 aut | |
| 700 | 0 | |a ESMAGAMBETOV ILIAS BULATOVICH |4 aut | |
| 700 | 0 | |a TOKARSKAYA ELIZAVETA ALEXANDROVNA |4 aut | |
| 700 | 0 | |a BOTIKOV ANDREI GENNADIEVICH |4 aut | |
| 700 | 0 | |a EROKHOVA ALINA SERGEEVNA |4 aut | |
| 700 | 0 | |a IZHAEVA FATIMA MAGOMEDOVNA |4 aut | |
| 700 | 0 | |a NIKITENKO NATALIA ANATOLIEVNA |4 aut | |
| 700 | 0 | |a LUBENETS NADEZHDA LEONIDOVNA |4 aut | |
| 700 | 0 | |a SEMIKHIN ALEKSANDR SERGEEVICH |4 aut | |
| 700 | 0 | |a CHERNETSOV VLADIMIR ALEKSANDROVICH |4 aut | |
| 700 | 0 | |a KRIUKOV EVGENII VLADIMIROVICH |4 aut | |
| 700 | 0 | |a BABIRA VLADIMIR FEDOROVICH |4 aut | |
| 700 | 0 | |a KUTAEV DMITRII ANATOLIEVICH |4 aut | |
| 700 | 0 | |a LOGINOVA SVETLANA YAKOVLEVNA |4 aut | |
| 700 | 0 | |a NARODITSKY BORIS SAVELIEVICH |4 aut | |
| 700 | 0 | |a LOGUNOV DENIS YURYEVICH |4 aut | |
| 700 | 0 | |a GINTSBURG ALEKSANDR LEONIDOVICH |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 27. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:27 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/81845625/publication/EP4295153A1?q=EP4295153 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 27 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 27 |c 12 | ||